Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/CLARA study. Submitted to ASH 2015 meeting.Thomas, X., S. De Botton, S. Chevret, D. Caillot, E. Raffoux, ...
We observed a significant reduction in risk of non-relapse mortality (NRM) over time (HR = 0.34, 95% CI 0.12–0.98; P = 0.05), the 4-year NRM estimate decreased from 20% in 2005–2008 to 7% in 2012–2016 (P = 0.02) and an increase in survival after relapse. There...
Normal karyotype acute myeloid leukemia (NK-AML) is a heterogeneous hematological malignancy that contains a minor population of self-renewing leukemia stem cells (LSCs), which complicate efforts to achieve long-term survival. We performed single-cell RNA sequencing to profile 39,288 cells from 6 ...
Overall survival in t-AML subgroups: treatment modality and age Median OS was 24 months in the entire cohort (95% CI 19.5–28.5) and 5-year OS was 36.6% respectively. In intensively treated patients, OS was significantly inferior (p < 0.001) in t-AML as compared to de novo AML (...
on day 0. Then the mice in each group were orally administered the corresponding medication (by mouth; gavage). Luminescence of each mouse was assessed over time (day 7 and day 14) to reflect treatment response. The clinical behavior, appearance, body weight, and survival were also monitored...
Separately, the PHOENIX survival data collection efforts will continue at the encouragement of ALS specialists. Risks and Uncertainties The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, the outcome of preclinical studies...
not relapse in younger intensively treated patients (P < .0001 and P = .39, respectively), relapse but not death in complete remission in older, less intensively treated patients (P = .02 and P = .22, respectively) and overall survival in younger intensively treated patients (P = .01)....
11,12 The 20% blast threshold was eliminated from the diagnostic criteria based on the fact that the NPM1-mutated myeloid neoplasms with less than 20% blasts are associated with shorter survival compared with wild-type cases and can benefit most from upfront intensive (AML-type) treatment ...
Patients who achieved CR with MRD negativity had the lowest rates of relapse and best survival (2-year overall survival rate, 37%), which was driven largely by lower rates of early relapse and an increased ability in this group to undergo hematopoietic stem cell transplantation (HSCT); however...
The standard induction chemotherapy regimens have not substantially changed over the past 40 years (Pulte et al., 2008). Most patients initially respond to chemotherapy and achieve a complete remission (CR), but only a minority achieves long-term survival because of relapse with chemoresistant ...